With psilocybin under the favourites within psychedelics, CoreOne Labs Inc. CLBF joins Optimal health OPTHF formally begin selling its own API psilocybin biosynthetic product.
On August 26, the company began talks with a Development and manufacturing partner regarding the commercial scale and GMP compliant production of Core One’s Active Pharmaceutical Ingredient (API) psilocybin product.
To this end, Core One representatives contacted several pharmaceutical and publicly traded psychedelics companies in need of psychedelics studies and Tryas well as medical clinics, professionals and organizations conducting psychedelic research or therapy with whom they shared the news of Availability of Proprietary Psilocybin. The company’s business approach includes complementary business areas and units. In addition to the work of its subsidiaries Psilocybin Production System with artificial bacteria, Psychedelics-Based Novel Compounds and other synthetic technologies Core One holds an interest in psilocybin and psilocin production methods four medical clinics with a combined database of more than 275,000 patients.
“Our cost-effective biosynthetic API psilocybin is attracting strong interest from companies and research groups seeking a supply of psilocybin,” said Joel Shacker, CEO of Core One. “I believe Core One will become a leader in the supply of psilocybin because it is one of the first companies to bring an API-grade compound to market, as well as the other competitive advantages that the company has.”
Photo courtesy of Olia Danilevich on Pexels.
